共 50 条
- [1] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Dieras, V.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceJassem, J.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceDirix, L. Y.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceGuastalla, J. P.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceBono, P.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceHurvitz, S. A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceGoncalves, A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceRomieu, G.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceLimentani, S. A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceJerusalem, G. H. M.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceLakshmaiah, K.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceRoche, H. H.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceSanchez-Rovira, P.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FrancePienkowski, T.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceSegui-Palmer, M. A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceLi, A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceSun, Y.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FrancePickett-Gies, C. A.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, FranceWildiers, H.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, France
- [2] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732Delaloge, S.论文数: 0 引用数: 0 h-index: 0机构: Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FrancePerol, D.论文数: 0 引用数: 0 h-index: 0机构: Ctr Leon Berard, Dept Biostat, Lyon, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceCourtinard, C.论文数: 0 引用数: 0 h-index: 0机构: R&D Unicanc, Dept Res & Dev, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceBrain, E.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, France Inst Curie, Dept Med Oncol, St Cloud, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceAsselain, B.论文数: 0 引用数: 0 h-index: 0机构: R&D Unicanc, Dept Res & Dev, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceBachelot, T.论文数: 0 引用数: 0 h-index: 0机构: Ctr Leon Berard, Dept Biostat, Lyon, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceDebled, M.论文数: 0 引用数: 0 h-index: 0机构: Inst Bergonie, Dept Med Oncol, Bordeaux, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceDieras, V.论文数: 0 引用数: 0 h-index: 0机构: Inst Curie, Dept Med Oncol, Paris, France Inst Curie, Dept Med Oncol, St Cloud, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceCampone, M.论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Ouest, Dept Med Oncol, Nantes, France Inst Cancerol Ouest, Dept Med Oncol, Angers, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceLevy, C.论文数: 0 引用数: 0 h-index: 0机构: Ctr Francois Baclesse, Dept Med Oncol, Caen, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceJacot, W.论文数: 0 引用数: 0 h-index: 0机构: Inst Canc Montpellier, Dept Med Oncol, Montpellier, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceLorgis, V.论文数: 0 引用数: 0 h-index: 0机构: Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceVeyret, C.论文数: 0 引用数: 0 h-index: 0机构: Ctr Henri Becquerel, Dept Med Oncol, Rouen, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceDalenc, F.论文数: 0 引用数: 0 h-index: 0机构: IUCT Oncopole, Inst Claudius Regaud, Dept Med Oncol, Toulouse, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceFerrero, J. M.论文数: 0 引用数: 0 h-index: 0机构: Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceUwer, L.论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceKerbrat, P.论文数: 0 引用数: 0 h-index: 0机构: Ctr Eugene Marquis, Dept Med Oncol, Rennes, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceGoncalves, A.论文数: 0 引用数: 0 h-index: 0机构: Inst Paoli Calmettes, Dept Med Oncol, Marseille, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceMouret-Reynier, M. A.论文数: 0 引用数: 0 h-index: 0机构: Ctr Jean Perrin, Dept Med Oncol, Clermont Ferrand, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FrancePetit, T.论文数: 0 引用数: 0 h-index: 0机构: Ctr Paul Strauss, Dept Med Oncol, Strasbourg, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceJouannaud, C.论文数: 0 引用数: 0 h-index: 0机构: Inst Cancerol Jean Godinot, Dept Med Oncol, Reims, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceVanlemmens, L.论文数: 0 引用数: 0 h-index: 0机构: Ctr Oscar Lambret, Dept Med Oncol, Lille, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceChenuc, G.论文数: 0 引用数: 0 h-index: 0机构: Capionis, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceGuesmia, T.论文数: 0 引用数: 0 h-index: 0机构: R&D Unicanc, Dept Res & Dev, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceRobain, M.论文数: 0 引用数: 0 h-index: 0机构: R&D Unicanc, Dept Res & Dev, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, FranceCailliot, C.论文数: 0 引用数: 0 h-index: 0机构: R&D Unicanc, Dept Res & Dev, Paris, France Inst Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France
- [3] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.CANCER RESEARCH, 2011, 71Beslija, S.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegBrodowicz, T.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegGreil, R.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegInbar, M. J.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegKahan, Z.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegKaufman, B.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegLang, I.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegSteger, G. G.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegStemmer, S. M.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegZielinski, C.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & HercegZvirbule, Z.论文数: 0 引用数: 0 h-index: 0机构: CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg
- [4] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trialEUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088Lam, S. W.论文数: 0 引用数: 0 h-index: 0机构: Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlandsde Groot, S. M.论文数: 0 引用数: 0 h-index: 0机构: Comprehens Canc Ctr Netherlands, Amsterdam, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsHonkoop, A. H.论文数: 0 引用数: 0 h-index: 0机构: Isala Clin, Zwolle, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsJager, A.论文数: 0 引用数: 0 h-index: 0机构: Dr Daniel Den Hoed Canc Ctr, Erasmus Med Ctr, NL-3008 AE Rotterdam, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlandsten Tije, A. J.论文数: 0 引用数: 0 h-index: 0机构: Tergooi Hosp, Hilversum, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsBos, M. M. E. M.论文数: 0 引用数: 0 h-index: 0机构: Reinier de Graaf Hosp, Delft, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsLinn, S. C.论文数: 0 引用数: 0 h-index: 0机构: Antoni van Leeuwenhoek, Netherlands Canc Inst, Amsterdam, Netherlands Univ Med Ctr Utrecht, Utrecht, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlandsvan den Bosch, J.论文数: 0 引用数: 0 h-index: 0机构: Albert Schweitzer Hosp, Dordrecht, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsKroep, J. R.论文数: 0 引用数: 0 h-index: 0机构: Leiden Univ, Med Ctr, Leiden, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsBraun, J. J.论文数: 0 引用数: 0 h-index: 0机构: Vlietland Hosp, Schiedam, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlandsvan Tinteren, H.论文数: 0 引用数: 0 h-index: 0机构: Antoni van Leeuwenhoek, Netherlands Canc Inst, Amsterdam, Netherlands Univ Med Ctr Utrecht, Utrecht, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, NetherlandsBoven, E.论文数: 0 引用数: 0 h-index: 0机构: Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands
- [5] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational StudyANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407Dieras, Veronique论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FrancePop, Simona论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceBerger, Frederique论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Biostat Unit, Paris, France PSL Res Univ, Inst Curie, INSERM, U900, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceDujaric, Marie-Eglantine论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Biostat Unit, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceBeuzeboc, Philippe论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceEscalup, Laurence论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Pharm Dept, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceBidard, Francois Clement论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, INSERM, U900, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceCottu, Paul Henri论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceLe Tourneau, Christophe论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FrancePiperno-Neumann, Sophie论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceLaurence, Valerie论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceRobain, Mathieu论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Biostat Unit, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FranceAsselain, Bernard论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Biostat Unit, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, FrancePierga, Jean-Yves论文数: 0 引用数: 0 h-index: 0机构: PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France Descartes Univ Paris, Paris, France PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France
- [6] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast CancerANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438论文数: 引用数: h-index:机构:Tanner, Minna论文数: 0 引用数: 0 h-index: 0机构: Univ Tampere, Sch Med, Dept Oncol, Tampere, Finland Tampere Univ Hosp, Dept Oncol, Teiskontie 35, Tampere 33521, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, FinlandLahdenpera, Outi论文数: 0 引用数: 0 h-index: 0机构: Turku Univ, Dept Oncol, Cent Hosp, Turku, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, Finland论文数: 引用数: h-index:机构:Jukkola, Arja论文数: 0 引用数: 0 h-index: 0机构: Oulu Univ Hosp, Dept Radiotherapy & Oncol, Med Res Ctr Oulu, Oulu, Finland Univ Oulu, Oulu, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, FinlandKarihtala, Peeter论文数: 0 引用数: 0 h-index: 0机构: Oulu Univ Hosp, Dept Radiotherapy & Oncol, Med Res Ctr Oulu, Oulu, Finland Univ Oulu, Oulu, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, FinlandPaunu, Niina论文数: 0 引用数: 0 h-index: 0机构: Tampere Univ Hosp, Dept Oncol, Teiskontie 35, Tampere 33521, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, FinlandHuttunen, Teppo论文数: 0 引用数: 0 h-index: 0机构: Oy 4 Pharma Ltd, Turku, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, FinlandKellokumpu-Lehtinen, Pirkko-Liisa论文数: 0 引用数: 0 h-index: 0机构: Univ Tampere, Sch Med, Dept Oncol, Tampere, Finland Tampere Univ Hosp, Dept Oncol, Teiskontie 35, Tampere 33521, Finland Univ Tampere, Sch Med, Dept Oncol, Tampere, Finland
- [7] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerCLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166Salvador, J.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ de Valme, Dept Oncol, Seville 28007, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainManso, L.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Dept Oncol, Madrid, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, Spainde la Haba, J.论文数: 0 引用数: 0 h-index: 0机构: Hosp Reina Sofia, Dept Oncol, Cordoba, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainJaen, A.论文数: 0 引用数: 0 h-index: 0机构: Hosp Jaen, Dept Oncol, Jaen, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainCiruelos, E.论文数: 0 引用数: 0 h-index: 0机构: Hosp Univ 12 Octubre, Dept Oncol, Madrid, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, Spainde Villena, M. C.论文数: 0 引用数: 0 h-index: 0机构: Hosp Virgen Macarena, Dept Oncol, Seville, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainGil, M.论文数: 0 引用数: 0 h-index: 0机构: ICO, Dept Oncol, Belvitge, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainMurias, A.论文数: 0 引用数: 0 h-index: 0机构: Hosp Insular Gran Canaria, Dept Oncol, Las Palmas Gran Canaria, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainGalan, A.论文数: 0 引用数: 0 h-index: 0机构: Hosp Sagunto, Dept Oncol, Sagunto, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainJara, C.论文数: 0 引用数: 0 h-index: 0机构: Hosp F Alcorcon, Dept Oncol, Alcorcon, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainBayo, J.论文数: 0 引用数: 0 h-index: 0机构: Hosp Juan Ramon Jimenez, Dept Oncol, Huelva, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainBaena, J. M.论文数: 0 引用数: 0 h-index: 0机构: Hosp Puerta Mar, Dept Oncol, Cadiz, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainCasal, J.论文数: 0 引用数: 0 h-index: 0机构: Hosp Meixoeiro, Dept Oncol, Vigo, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainMel, J. R.论文数: 0 引用数: 0 h-index: 0机构: Hosp Xeral Calde, Dept Oncol, Lugo, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainBlancas, I.论文数: 0 引用数: 0 h-index: 0机构: Hosp Clin Univ, Dept Oncol, Valencia, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, SpainSanchez Rvira, P.论文数: 0 引用数: 0 h-index: 0机构: Hosp Jaen, Dept Oncol, Jaen, Spain Hosp Univ de Valme, Dept Oncol, Seville 28007, Spain
- [8] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancerClinical and Translational Oncology, 2015, 17 : 160 - 166J. Salvador论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyL. Manso论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyJ. de la Haba论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyA. Jaen论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyE. Ciruelos论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyM. C. de Villena论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyM. Gil论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyA. Murias论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyA. Galan论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyC. Jara论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyJ. Bayo论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyJ. M. Baena论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyJ. Casal论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyJ. R. Mel论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyI. Blancas论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of OncologyP. Sanchez Rvira论文数: 0 引用数: 0 h-index: 0机构: Hospital Universitario de Valme,Department of Oncology
- [9] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast CancerCLINICAL BREAST CANCER, 2012, 12 (05) : 322 - 330Borson, Rachel论文数: 0 引用数: 0 h-index: 0机构: St Louis Canc & Breast Inst, Mercy Clin, St Louis, MO USA Sarah Cannon Res Inst, Nashville, TN USAHarker, Graydon论文数: 0 引用数: 0 h-index: 0机构: Utah Canc Specialists, Salt Lake City, UT USA Sarah Cannon Res Inst, Nashville, TN USAReeves, James论文数: 0 引用数: 0 h-index: 0机构: Mercy Hosp, Oklahoma City, OK USA Sarah Cannon Res Inst, Nashville, TN USABeck, Thaddeus论文数: 0 引用数: 0 h-index: 0机构: Highlands Oncol Grp, Fayetteville, AR USA Sarah Cannon Res Inst, Nashville, TN USAHager, Steven论文数: 0 引用数: 0 h-index: 0机构: Canc Care Associates Fresno, Fresno, CA USA Sarah Cannon Res Inst, Nashville, TN USAHorvath, William论文数: 0 引用数: 0 h-index: 0机构: HOA Canc Ctr, Sylvania, OH USA Sarah Cannon Res Inst, Nashville, TN USAJones, Michael论文数: 0 引用数: 0 h-index: 0机构: Jones Clin, Germantown, TN USA Sarah Cannon Res Inst, Nashville, TN USATillinghast, Guy论文数: 0 引用数: 0 h-index: 0机构: Riverside Canc Care Ctr, Newport News, VA USA Sarah Cannon Res Inst, Nashville, TN USAArrowsmith, Edward论文数: 0 引用数: 0 h-index: 0机构: Chattanooga Oncol Associates, Chattanooga, TN USA Sarah Cannon Res Inst, Nashville, TN USAHarrer, Grant论文数: 0 引用数: 0 h-index: 0机构: Sletten Canc Inst, Great Falls, MT USA Sarah Cannon Res Inst, Nashville, TN USAKudrik, Fred J.论文数: 0 引用数: 0 h-index: 0机构: S Carolina Oncol Associates, Columbia, SC USA Sarah Cannon Res Inst, Nashville, TN USAMalamud, Stephen C.论文数: 0 引用数: 0 h-index: 0机构: Beth Israel Deaconess Med Ctr, New York, NY 10003 USA Sarah Cannon Res Inst, Nashville, TN USABromund, Jane论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Indianapolis, IN 46285 USA Sarah Cannon Res Inst, Nashville, TN USAZeigler, Haoyue论文数: 0 引用数: 0 h-index: 0机构: PharmaNeti3, InVentiv Hlth Co, Indianapolis, IN USA PharmaNeti3, InVentiv Hlth Co, Blue Bell, PA USA Sarah Cannon Res Inst, Nashville, TN USATai, Datchen Fritz论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Indianapolis, IN 46285 USA Sarah Cannon Res Inst, Nashville, TN USAKornberg, Lori J.论文数: 0 引用数: 0 h-index: 0机构: PharmaNeti3, InVentiv Hlth Co, Indianapolis, IN USA PharmaNeti3, InVentiv Hlth Co, Blue Bell, PA USA Sarah Cannon Res Inst, Nashville, TN USAObasaju, Coleman论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Indianapolis, IN 46285 USA Sarah Cannon Res Inst, Nashville, TN USAOrlando, Mauro论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Indianapolis, IN 46285 USA Sarah Cannon Res Inst, Nashville, TN USAYardley, Denise A.论文数: 0 引用数: 0 h-index: 0机构: Sarah Cannon Res Inst, Nashville, TN USA PLLC, Tennessee Oncol, Nashville, TN USA Sarah Cannon Res Inst, Nashville, TN USA
- [10] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Masuda, N.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanAogi, K.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanOhno, S.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanIwata, H.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanKashiwaba, M.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanFujiwara, Y.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanIto, Y.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanUeno, T.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanSaijo, N.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, JapanTakashima, S.论文数: 0 引用数: 0 h-index: 0机构: Natl Hosp Org Osaka Natl Hosp, Osaka, Japan